



# **Welcome and Introduction**

#### **Veronica Miller**

Forum for Collaborative Research



## **Steering Committee**

Veronica Miller Forum for Collaborative Research

**Co-Chairs** 

Michelle Berrey, Chimerix, Inc.

Per Ljungman, Karolinska Institutet

Academia

Industry

Lesia Dropulic, NIH/NIAID

Filip Josephson, EMA

Takashi Komatsu, FDA/CDER

Regulatory

Philip Krause, FDA/CBER

Li Li, FDA/CDRH

Jeff Murray, FDA/CDER

Jules O'Rear, FDA/CDER

Michael Boeckh, Fred Hutchinson Cancer Research Center

Paul Griffiths, University College London

Atul Humar, University of Toronto

Peter Hunt, University of California, San Francisco

Paul Baum, Roche Molecular Systems

Jay Erdman, Astellas Pharma, Inc.

Randi Leavitt, Merck Research Labs

Danijela Lucic, Abbott Molecular



For Collaborative Researce

# **CMV Forum 4 RECAP**



- Now is the time to re-focus on virologic and immunologic assessments
  - Diagnostics
  - Endpoints
- Consider other transplantation related viruses



### **Recent Accomplishments**

 Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials
Roy F. Chemaly, Sunwen Chou, Hermann Einsele, Paul Griffiths, Robin Avery, Raymund R. Razonable, Kathleen M. Mullane, Camille Kotton, Jens Lundgren, Takashi E. Komatsu, Peter Lischka, Filip Josephson, Cameron M. Douglas, Obi Umeh, Veronica Miller, Per Ljungman; for the Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum.



# **Work in Progress**

#### Focus on CMV Diagnostics

- Formed two sub-groups to address the virological and immunological endpoints of CMV diagnostics.
- Resistant / Refractory Working Group





### **Sponsors**

















